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The emergence of leukemia-speciﬁc cytotoxic T lymphocytes
and their putative protective role against disease progression
have recently been described in patients undergoing imatinib
mesylate (IM) therapy, affected by either chronic myeloid
leukemia or Philadelphia chromosome-positive acute lympho-
blastic leukemia (Ph
þALL).
1,2 In particular, we have reported
the immunological monitoring of 10 Ph
þALL patients during
long-term IM maintenance treatment, demonstrating the inverse
correlation between the frequencies of cytotoxic
p190BCR–ABL-
speciﬁc T cells in the bone marrow (BM) and minimal residual
disease (MRD) values.
2 Whether similar autologous
p190BCR–
ABL-speciﬁc immune responses may be detectable and asso-
ciated with the disease course under second-generation
tyrosine-kinase inhibitors (TKIs), remains to be assessed.
To address this issue, we have prospectively analyzed ﬁve
Ph
þALL patients treated with either dasatinib or nilotinib
(Figure 1a). Patient 1 was a 60-year-old woman, who switched
from a 3-years IM maintenance (800mg/die) to dasatinib
therapy (140mg/die since June 2007; reduction to 100mg/die
since December 2007 and to 70mg/die since October 2008),
due to molecular relapse with fast-growing MRD values. The
patient rapidly achieved a second complete molecular remis-
sion of the disease, but then (February 2009), she was switched
to nilotinib (800mg/die) because of recurrent episodes of severe
ﬂuid retention with pleural effusions. At present, she is well and
still in complete molecular remission. Patient 2 was a 66-year-
old woman, presenting a marked increment of the MRD
on month 53 (January 2007) of a 4-years IM maintenance
(800mg/die). The patient was switched to dasatinib (140mg/die;
reduction to 100mg/die since March 2007 and to 70mg/die
since November 2007) and achieved the control of the disease.
Three years later (August 2010), she presented with severe
cardiac toxicity and died of heart failure, still in complete
hematologic remission. Patient 3 was a 66-year-old man, who
was started on IM (800mg/die) and steroids. The patient
obtained complete molecular remission of leukemia and was
subsequently maintained with IM alone (800mg/die). Even-
tually, after 5 months (March 2010), the patient showed
hematologic relapse and underwent therapy with dasatinib
alone (140mg/die; reduction to 100mg/die since April 2010),
obtaining a second complete hematologic remission of leuke-
mia. The patient was lost in follow-up still in complete hemato-
logic remission. Patients 4 and 5, a 57- and 56-year-old man,
respectively, were treated upfront with dasatinib (140mg/die;
reduction to 100mg/die since September 2007 and October
2007, respectively), obtaining complete hematologic remission.
Both patients underwent allogeneic stem cell transplantation,
because of either hematologic relapse or the progressive
increase of MRD values, after 7 months (November 2007) and
8 months (January 2008) of treatment, respectively.
All patients underwent monthly collection of BM and
peripheral blood samples (total of 59 samples) for either MRD
or immunological monitoring (median follow-up time 11
months, range 8–43 months). The latter has been performed
through an interferon-g (IFNg) enzyme-linked immunospot
assay, using, as antigenic stimulation, different pools of short
and long peptides (9–20 mers), deriving from the complete
spanning of
p190BCR–ABL protein fusion region, as previously
described.
2 IFNg-producing
p190BCR–ABL-speciﬁc T cells were
observed in ﬁve out of ﬁve (100%) Ph
þALL patients under
second-generation TKIs. The median number of
p190BCR–ABL-
speciﬁc T cells resulted 54.7±17.4 spot forming cells/10
6cells
(range 35–78) upon nilotinib and 27.5±28.4 spot forming cells/
10
6cells (range 20–115) upon dasatinib, respectively. The
comparison, through the median test, between the frequencies
of anti-leukemic T cells detected upon dasatinib and nilotinib and
those observed upon IM therapy (median spot forming cells/
10
6 cells 70.3±79.7; range 20–350) in the 10 Ph
þALL patients
previously reported,
2 demonstrated statistical signiﬁcant
differences between IM and dasatinib (P¼0.01) and between
nilotinib and dasatinib (P¼0.003), but not between IM and
nilotinib (P¼0.85) (Figure 1b). Moreover,
p190BCR–ABL-speciﬁc
T cells were more frequently detectable in BM than peripheral
blood samples (62.2 vs 20%, Po0.01), as early as 45 days
from the beginning of the treatment, and were associated with
MRD values lower than 10
 3, in a statistically signiﬁcant
manner (Po0.001). In addition, the dynamics of
p190BCR–ABL-
speciﬁc BM T cells appeared to be inversely correlated with the
kinetics of MRD by showing the following: (a) increased or
sustained number of speciﬁc T cells with either absent or
decreasing MRD values (patients 1–3); (b) decreasing number or
absence of speciﬁc T cells with growing MRD values (patients
2–5) or with hematologic relapse (patient 4) (Figure 1a).
Furthermore, we have functionally characterized the
p190BCR–ABL-speciﬁc T cells through a cytokine secretion assay
for IFNg, tumor necrosis factor-a or interleukin-2, as previously
described.
2 IFNg-producing speciﬁc immune responses were
conﬁrmed in all patients (median percentage of positive
cells: 1.48, range 0.1–2.8), mediated mainly by CD8þ T cells
(median 0.86%) and, to a lower extent, by CD4þ
T lymphocytes (median 0.62%). The former showed a pre-
dominantly effector memory (EM) phenotype (median
EM/central memory frequencies 0.52%/0.34%), whereas the latter
were either EM (0.33%) or central memory (0.29%) (Figure 1c).
p190BCR–ABL-speciﬁc tumor necrosis factor-a-secreting T cells
were also detected at similar frequencies (median % positive
cells: 1.51, range 0.1–2.7), due to not only CD8þ lymphocytes,
either EM (0.56%) or central memory (0.41%) subsets, but also
to CD4þ T cells, predominantly of EM phenotype (median EM/
central memory frequencies 0.43%/0.11%) (Figure 1c). More-
over, interleukin-2-producing speciﬁc T-cell responses were
detected at lower frequencies (median % positive cells: 0.38,
range 0.1–0.7) and almost equally distributed between CD8þ
and CD4þ T lymphocytes, mostly of EM phenotype (Figure 1c).
In two out of three patients tested (patients 1, 3, 5),
p190BCR–
ABL-speciﬁc cytotoxic CD8þ and CD4þ T-cell subsets were
expandable ex-vivo in short-term BM cultures, and were demon-
strated to be able to speciﬁcally lyse
p190BCR–ABL-positive
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p190BCR–ABL-derived
peptides, using standard
51chromium-release cytotoxicity assays
(speciﬁc lysis: 2500 and 5263LU10/10
5, respectively), per-
formed as previously described.
2 Of note, in patient 1, similar
levels of leukemia-speciﬁc lysis were shown by different
p190BCR–ABL-speciﬁc cytotoxic T cells, derived from BM
samples obtained during initial IM maintenance, later on,
during dasatinib treatment, and, eventually, after the switch to
nilotinib (Figure 1d).
In this work, by applying different antigen-speciﬁc immuno-
logical assays (namely, IFNg-enzyme-linked immunospot,
cytokine secretion assay and
51chromium-release cytotoxicity
assays), we have demonstrated that
p190BCR–ABL speciﬁc T-cell
responses may occur in Ph
þALL patients also during second-
generation TKIs therapy. Similarly to those previously observed
under IM maintenance therapy in the same clinical setting,
2
such leukemia-speciﬁc T cells may emerge early in the course of
the treatment and ﬂuctuate or persist for several months, mainly
reside in BM, may be maintained or recovered by switching
from a TKI to another, are signiﬁcantly associated with lower
MRD values and able to either produce cytotoxic cytokines or
mediate leukemia-speciﬁc lysis. Although the median frequencies
Figure 1 (a) Immunological monitoring of
p190BCR–ABL-speciﬁc memory T-cell responses in the BM of ﬁve Phþ ALL patients on TKIs therapy,
and correlation with the disease course. Longitudinal data tracking MRD kinetics (right, y axis; continuous line with black squares) and IFNg-
producing
p190BCR–ABL-speciﬁc T-cell responses as detected by the enzyme-linked immunospot assay (left, y axis, dotted line with white squares)
are summarized in a single time-course graph (months, x axis) for each patient (patient (pt.) 1–5). Imatinib¼dark gray bar; dasatinib¼white bar;
nilotinib¼light gray bar. AlloSCT¼allogeneic stem cell transplantation; BMMCs¼bone marrow mononuclear cells; CHT¼consolidation
chemotherapy; IFNg¼interferon g;R T¼central nervous system radiotherapeutic prophylaxis; SFC¼spot forming cells. (b) Median frequencies of
p190BCR–ABL-speciﬁc T cells upon treatment with the different TKIs. Dashed lines represent the median values. The upper and lower hinges of the
boxes represent the 75th percentile and the 25th percentile values, respectively. Dots represent outside values. Statistically signiﬁcant differences
are indicated. (c, d) Analysis of cytokine proﬁle and cytolytic activity of
p190BCR–ABL-speciﬁc BM T cells from the Phþ ALL patients. (c) The
frequencies of
p190BCR–ABL speciﬁc BM T cells producing IFNg, tumor necrosis factor (TNF)-a or interleukin-2, either as effector memory (CCR7 )
(EM, gray) or central memory (CCR7þ) (CM, white), from all the ﬁve patients, are shown in columns as median percentage of positive cells, and
expressed as percentages of CD8
þ or CD4
þ T cells. Single values of speciﬁc cytokine-producing T cells are represented on each column, either as
EM (J)o rC M( &). (d) Cytotoxicity proﬁle of cultured BMMCs obtained from pt.1 under treatment with different TKIs. The ﬁgure reports
percentage of speciﬁc lysis against autologous PHA blasts pulsed with
p190BCR–ABL peptides of BMMC cultured for 13 days in the presence of
p190BCR–ABL-derived peptides and obtained during imatinib (continuous black line with black squares), dasatinib (segmented black line with
black triangles) and nilotinib treatment (dotted black line with black dots). The mean percentage of lysis of duplicate wells for six different effector
to target (E:T) ratios is shown.
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p190BCR–ABL-speciﬁc T cells seem higher upon IM and
nilotinib than upon dasatinib, the number of patients studied is
too small to draw any ﬁrm conclusion. Moreover, data from the
literature about the effect of dasatinib on the immune system are
still controversial. Several in vitro studies have reported that
dasatinib, more than IM and nilotinib, may exert a suppressive
activity on the development and function of adaptive immunity,
due to the additional inhibition of the Src-family kinases.
3,4
Nonetheless, recent clinical observations have demonstrated
that dasatinib treatment may induce chronic mono/oligoclonal
large granular lymphocytes proliferations, of either natural killer
or natural killer/T phenotype in the patients’ peripheral blood,
which are strongly associated with the improvement of patients’
outcome.
5–7 Of note, none of our Ph
þALL patients under
dasatinib developed clinically signiﬁcant large granular lym-
phocytes proliferation in the peripheral blood, but an increase of
the natural killer/T and natural killer subsets was observed in
their BM (data not shown), consistently with the BM immune
proﬁle of chronic myeloid leukemia patients treated with TKIs,
recently reported.
8
The immunomodulatory effects of TKI treatment on genera-
tion, function and maintenance of anti-leukemic immunity are
still largely unclear. Regarding to this issue, our data seem to
suggest that long-term therapy with either ﬁrst or second
generation TKIs, despite prevalent inhibitory effects on T-cell
proliferation and functions in vitro, may not exert the expected
suppressive activity on patients’ anti-leukemic immune cells.
Furthermore, the continuous killing of Ph
þ blasts by TKI therapy
could be functional to provide an optimal amount of tumor
antigens, this having, in turn, a pivotal role for maintaining and
shaping the protective speciﬁc T-cell repertoire. In our series of
Ph
þALL patients, treated with either ﬁrst
2 or second generation
TKIs, the detection of
p190BCR–ABL-speciﬁc T cells was
signiﬁcantly associated with lower levels of MRD. However,
these speciﬁc cytotoxic T cells may likely constitute one subset
of the total anti-leukemic immunity occurring in Ph
þALL
patients, as other leukemia-associated antigens have been
reported to be immunogenic targets in Ph
þALL in different
therapeutic settings.
9,10
In conclusion, in vivo data, both from this report and the
literature, seem to suggest that, although preferentially prompt-
ing the innate immunity, also dasatinib, as well as the other
TKIs, may allow the emergence of leukemia-speciﬁc T cells with
direct anti-leukemic activity and, possibly, contributing to the
control of the disease. Additional studies on larger cohorts of
patients are warranted to conﬁrm our ﬁndings, to deﬁne all the
factors affecting the occurrence and persistence of
p190BCR–
ABL-speciﬁc immune responses, and to investigate whether
such speciﬁc T cells or other speciﬁc immune responses to
different leukemia-associated antigens may be harnessed either
as further prognostic factors or as a novel source for autologous
T-cell therapy in Ph
þALL patients, during TKIs maintenance
treatment.
Conﬂict of interest
The authors declare no conﬂict of interest.
Acknowledgements
This study was supported by grants from the Associazione Italiana
per la Ricerca sul Cancro (AIRC), Milan, Italy (ML, and PC); the
Associazione Italiana Lotta alle Leucemie, Linfoma e Mieloma
(AIL)FSezione ‘Luciano Pavarotti’FModena-ONLUS (LP and
FF); Programma di ricerca Regione-Universita‘ (PRU 2007–2009)
Emilia Romagna (ML); and Ministero della Salute, Progetti Ricerca
Oncologica (RFPS-2006-4-341763 (PC), RFPS-2006-Regione
Umbria (PC)).
G Riva
1,4, M Luppi
1,4, C Quadrelli
1,4, P Barozzi
1, S Basso
2,
D Vallerini
1, E Zanetti
1, M Morselli
1, F Forghieri
1,
M Maccaferri
1, A Paolini
1, C Del Giovane
1, R D’Amico
1,
R Marasca
1, F Narni
1, I Iacobucci
3, G Martinelli
3,
M Baccarani
3, P Comoli
2,5 and L Potenza
1,5
1Section of Hematology, Department of Oncology,
Hematology and Respiratory Diseases, University of Modena
and Reggio Emilia, Modena, Italy;
2Pediatric Hematology Oncology, Research Laboratories,
Istituto di Ricovero e Cura a Carattere Scientiﬁco (IRCCS),
Policlinico San Matteo, Pavia, Italy and
3Institute of Haematology and Medical Oncology ‘L. e A.
Seragnoli’, University of Bologna, Bologna, Italy
E-mail: mario.luppi@unimore.it
4These authors contributed equally to this work.
5These authors contributed equally to this work.
References
1 Chen CI, Maecker HT, Lee PP. Development and dynamics of
robust T-cell responses to CML under imatinib treatment. Blood
2008; 111: 5342–5349.
2 Riva G, Luppi M, Barozzi P, Quadrelli C, Basso S, Vallerini D et al.
Emergence of BCR-ABL-speciﬁc cytotoxic T cells in the
bone marrow of patients with Ph+ acute lymphoblastic leukemia
during long-term imatinib mesylate treatment. Blood 2010; 115:
1512–1518.
3 Blake S, Hughes TP, Mayrhofer G, Lyons AB. The Src/ABL kinase
inhibitor dasatinib (BMS-354825) inhibits function of normal
human T-lymphocytes in vitro. Clin Immunol 2008; 127: 330–339.
4 Schade AE, Schieven GL, Townsend R, Jankowska AM, Susulic V,
Zhang R et al. Dasatinib, a small-molecule protein tyrosine kinase
inhibitor, inhibits T-cell activation and proliferation. Blood 2008;
111: 1366–1377.
5 Mustjoki S, Ekblom M, Arstila TP, Dybedal I, Epling-Burnette PK,
Guilhot F et al. Clonal expansion of T/NK-cells during tyrosine
kinase inhibitor dasatinib therapy. Leukemia 2009; 23:
1398–1405.
6 Kim DH, Kamel-Reid S, Chang H, Sutherland R, Jung CW, Kim HJ
et al. Natural killer or natural killer/T cell lineage large
granular lymphocytosis associated with dasatinib therapy for
Philadelphia chromosome positive leukemia. Haematologica
2009; 94: 135–139.
7 Kreutzman A, Juvonen V, Kairisto V, Ekblom M, Stenke L,
Seggewiss R et al. Mono/oligoclonal T and NK cells are common
in chronic myeloid leukemia patients at diagnosis and expand
during dasatinib therapy. Blood 2010; 116: 772–782.
8 Rohon P, Porkka K, Mustjoki S. Immunoproﬁling of chronic
myeloid leukemia patients at diagnosis and during tyrosine kinase
inhibitor therapy. Eur J Haematol 2010; 85: 387–398.
9 Rezvani K, Yong AS, Savani BN, Mielke S, Keyvanfar K, Gostick E
et al. Graft-versus-leukemia effects associated with detectable
Wilms tumor-1 speciﬁc T lymphocytes after allogeneic stem-cell
transplantation for acute lymphoblastic leukemia. Blood 2007;
110: 1924–1932.
10 Rezvani K, Yong AS, Tawab A, Jafarpour B, Eniafe R, Mielke S et al.
Ex vivo characterization of polyclonal memory CD8+ T-cell
responses to PRAME-speciﬁc peptides in patients with acute
lymphoblastic leukemia and acute and chronic myeloid leukemia.
Blood 2009; 113: 2245–2255.
This work is licensed under the Creative Commons
Attribution-NonCommercial-No Derivative Works
3.0 Unported License. To view a copy of this license, visit http://
creativecommons.org/licenses/by-nc-nd/3.0/
Letter to the Editor
3
Blood Cancer Journal